GE Healthcare, Vanderbilt partner on AI-enabled precision medicine

Advances in cancer care such as immunotherapy promise greater success in treatment but also currently come with higher risks and uncertain outcomes. GE Healthcare and Vanderbilt University Medical Center are partnering to develop AI applications which will examine anonymized patient data to help physicians determine better courses of treatment. By retroactively analyzing demographic, genomic, tumor, cellular, proteomic and imaging data from anonymized patient records, these AI apps will assist clinicians in determining the best course of treatment for current and future patients. "This partnership is a great example of the increasing convergence of the tools, technologies and data used by therapy innovators and healthcare providers," said Kieran Murphy, president and CEO of GE Healthcare, in a statement. WHY IT MATTERS Because immunotherapies are expensive and have the potential to cause damage if the wrong therapy is chosen, they are still associated with increased mortalities and cost.